Researchers developing new cancer therapeutics based on the next generation oncolytic viruses have published initial results that demonstrate an anti-tumor immunity of oncolytic viruses -- published for the first time in humans -- and indicate the strong efficacy of the next generation viruses against solid tumor cancers.